RECRUITINGPhase 2INTERVENTIONAL
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
A Phase 2, Randomized, Open Label Study of AMDX-2011P as a Retinal Tracer in Participants With Primary Open Angle Glaucoma
About This Trial
The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).
Who May Be Eligible (Plain English)
Who May Qualify:
1. Diagnosis of primary open angle glaucoma in both eyes
2. Able to fixate
3. Glaucomatous optic nerve damage in both eyes, as determined by an investigator as part of an eye exam
Who Should NOT Join This Trial:
1. Participants unable to read or write
2. Ocular media is not sufficiently clear to obtain acceptable quality images
3. Participants with presence of any ocular pathology other than glaucoma in the study eye (cataracts are acceptable)
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. Diagnosis of primary open angle glaucoma in both eyes
2. Able to fixate
3. Glaucomatous optic nerve damage in both eyes, as determined by an investigator as part of an eye exam
Exclusion Criteria:
1. Participants unable to read or write
2. Ocular media is not sufficiently clear to obtain acceptable quality images
3. Participants with presence of any ocular pathology other than glaucoma in the study eye (cataracts are acceptable)
Treatments Being Tested
DRUG
AMDX-2011P
AMDX-2011P single bolus injection intravenous for diagnostic review
Locations (3)
Associated Retina Consultants
Phoenix, Arizona, United States
Global Research Management
Glendale, California, United States
Eye Research Foundation
Newport Beach, California, United States